VRDN
Viridian Therapeutics, Inc. (VRDN) 10Y Growth Potential Analysis (2026)
Overall Score
Revenue Growth
Revenue base remains small at $0.66 per share, leaving room for growth if commercialization scales.
No recent news or fresh metric evidence of a material change in top-line trajectory this month.
Profitability
Gross margin remains extremely high at 99.4%, but operating margin is deeply negative at -5.7% and net margin at -5.4%.
Return on equity is -61.3% and return on invested capital is -39.2%, indicating the business is still far from profitable.
Balance Sheet
Liquidity remains very strong with a current ratio of 16.9x and cash per share of $9.10.
Debt remains manageable with debt-to-equity at 0.37x and net debt-to-EBITDA still low at -0.21x.
Cash Flow
Free cash flow remains negative at -$110.9M TTM, with free cash flow yield at -13.3%.
Operating cash flow is also negative, so the company is still consuming cash rather than generating it.
Valuation
The stock still trades at a very rich EV/sales multiple of 36.5x, which leaves little room for execution misses.
Negative earnings and cash flow keep traditional valuation metrics difficult to anchor despite a strong cash position.
Growth Runway
The balance sheet provides runway for continued R&D and commercialization efforts.
However, the current operating losses mean long-term growth potential still depends on successful pipeline execution.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Viridian Therapeutics, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

